Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Humaidan

Showing results (11-20 of 262) with videos related to

Pageof 27
Sort By:
Current Opinion in Obstetrics & Gynecology|March 27, 2015
Ovarian hyperstimulation syndrome in the 21st century: the role of gonadotropin-releasing hormone agonist trigger and kisspeptinLise Thomsen, Peter Humaidan
Reproductive Biomedicine Online|February 2, 2019
Bureaucratic overheating is a parasite hampering modern clinical research - a viewpoint from the 'belly of the beast'Peter Humaidan, Thor Haahr
Reproductive Biomedicine Online|July 22, 2014
GnRHa trigger for final oocyte maturation: is HCG trigger history?Peter Humaidan, Birgit Alsbjerg
Translational Andrology and Urology|October 31, 2017
Testing of sperm DNA damage and clinical recommendationsPreben Christensen, Peter Humaidan
F&S Reports|May 24, 2023
GnRHa trigger-the story of the ugly ducklingPeter Humaidan, Thor Haahr
BMJ Open|July 3, 2024
Rectal versus vaginal progesterone administration for luteal phase support in the hormone replacement therapy frozen embryo transfer (HRT-FET) cycle: protocol for a non-inferiority randomised controlled trialBirgit Alsbjerg, Peter Humaidan
Reproductive Biology|February 9, 2017
GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept studySafak Olgan, Peter Humaidan
Human Reproduction Open|June 5, 2023
Caution is needed when communicating analyses based on an apple to orange comparisonBirgit Alsbjerg, Peter Humaidan
Reproductive Biomedicine Online|January 23, 2013
GnRH agonist triggering: recent developmentsShahar Kol, Peter Humaidan
Reproductive Biomedicine Online|August 2, 2025
Response: As with all innovations, it may take a considerable time to change policies - the case of in-vitro maturation (IVM) Safety first, but not necessarily at the cost of effectivenessBaris Ata, Peter Humaidan
Pageof 27

Showing results (11-20 of 262) with videos related to

Sort By:
Pageof 27
Current Opinion in Obstetrics & Gynecology|March 27, 2015
Ovarian hyperstimulation syndrome in the 21st century: the role of gonadotropin-releasing hormone agonist trigger and kisspeptinLise Thomsen, Peter Humaidan
Reproductive Biomedicine Online|February 2, 2019
Bureaucratic overheating is a parasite hampering modern clinical research - a viewpoint from the 'belly of the beast'Peter Humaidan, Thor Haahr
Reproductive Biomedicine Online|July 22, 2014
GnRHa trigger for final oocyte maturation: is HCG trigger history?Peter Humaidan, Birgit Alsbjerg
Translational Andrology and Urology|October 31, 2017
Testing of sperm DNA damage and clinical recommendationsPreben Christensen, Peter Humaidan
F&S Reports|May 24, 2023
GnRHa trigger-the story of the ugly ducklingPeter Humaidan, Thor Haahr
BMJ Open|July 3, 2024
Rectal versus vaginal progesterone administration for luteal phase support in the hormone replacement therapy frozen embryo transfer (HRT-FET) cycle: protocol for a non-inferiority randomised controlled trialBirgit Alsbjerg, Peter Humaidan
Reproductive Biology|February 9, 2017
GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept studySafak Olgan, Peter Humaidan
Human Reproduction Open|June 5, 2023
Caution is needed when communicating analyses based on an apple to orange comparisonBirgit Alsbjerg, Peter Humaidan
Reproductive Biomedicine Online|January 23, 2013
GnRH agonist triggering: recent developmentsShahar Kol, Peter Humaidan
Reproductive Biomedicine Online|August 2, 2025
Response: As with all innovations, it may take a considerable time to change policies - the case of in-vitro maturation (IVM) Safety first, but not necessarily at the cost of effectivenessBaris Ata, Peter Humaidan
Pageof 27